On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.

scientific article

On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/APT.13977
P698PubMed publication ID28252185

P50authorMario PirisiQ53754880
James R M BlackQ85231674
Clarence YenQ88032075
David J. PinatoQ88654157
Jessica HowellQ89393587
P2093author name stringR Sharma
C Ferrari
M Kudo
T Arizumi
J-W Park
D Bettinger
M E Burlone
R Thimme
R Ramaswami
L Sellers
A Gibbin
G Guaschino
P2860cites workPathological bacterial translocation in liver cirrhosisQ26824138
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaQ27860783
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Q27861047
Sorafenib in advanced hepatocellular carcinomaQ27861075
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialQ29547903
Hepatocellular carcinomaQ29615841
Microbiota-liver axis in hepatic disease.Q33855414
Altered profile of human gut microbiome is associated with cirrhosis and its complicationsQ35077209
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibQ35583678
Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase InhibitorsQ35685574
Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosisQ35790974
Toll-like receptor signaling in the liverQ36477368
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancerQ36614004
Focal gains of VEGFA and molecular classification of hepatocellular carcinomaQ36984575
Review article: the management of hepatocellular carcinomaQ37635285
Modified RECIST (mRECIST) assessment for hepatocellular carcinomaQ37696396
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosisQ37773059
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factorsQ37937406
On-target and off-target-based toxicologic effectsQ38053874
Medical therapies for hepatocellular carcinoma: a critical view of the evidenceQ38059437
Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacyQ38101885
Gut-liver immunity.Q38674310
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factorsQ39019421
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Q39030388
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.Q41489415
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenibQ43411812
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinomaQ45275265
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.Q50474760
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.Q53097045
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.Q53324924
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.Q53667125
P433issue8
P407language of work or nameEnglishQ1860
P921main subjecthepatocellular carcinomaQ1148337
P304page(s)1146-1155
P577publication date2017-03-02
P1433published inAlimentary Pharmacology & TherapeuticsQ4726656
P1476titleOn-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study
P478volume45

Reverse relations

cites work (P2860)
Q94475144A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
Q47954829An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
Q58793629Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
Q54521075Editorial: sorafenib toxicity, a biomarker of effect?
Q90302707Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC
Q100725420Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Q90674632Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib
Q90451914RAF1 Expression is Correlated with HAF, a Parameter of Liver Computed Tomographic Perfusion, and may Predict the Early Therapeutic Response to Sorafenib in Advanced Hepatocellular Carcinoma Patients
Q90436245Review article: systemic treatment of hepatocellular carcinoma
Q61054484Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis
Q57301434Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
Q57067866Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Q99240029Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
Q90644228Treatment Lines in Hepatocellular Carcinoma
Q57491231Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy

Search more.